Therapeutic Advances in Infectious Disease

A SAGE Open Access journal | Publishing high-quality articles in infectious disease | Editor-in-Chief @andhen25 | IF 3.8

[Therapeutic Advances in Infectious Disease @TAInfDis]

Neonatal sepsis remains alarmingly common in Ethiopia: pooled prevalence 29.9%, with 66.2% multidrug resistance. Klebsiella pneumoniae and E. coli predominated, showing high resistance to first-line antibiotics. https://t.co/EWDAZqYzXQ

[Therapeutic Advances in Infectious Disease @TAInfDis]

Adult HBV vaccination decisions are shaped not only by access barriers, but also by culturally embedded beliefs. Context-sensitive education + provider recommendations are key
https://t.co/USMnMAjW5E

[Therapeutic Advances in Infectious Disease @TAInfDis]

Do all patients with CIED infection need prolonged antibiotics? In this cohort, ≤2 weeks of therapy AFTER device extra extraction had similar mortality and recurrence rates compared with longer courses after complete device removal.
https://t.co/7yy3qMX5lY

[Therapeutic Advances in Infectious Disease @TAInfDis]

Late-onset CMV pneumonia can occur even 1 year after auto-HSCT, particularly in patients with profound CD4 lymphopenia. This case highlights the value of immune-guided surveillance and BALF mNGS in diagnosing complex infections in immunocompromised hosts.https://t.co/91D07iQPMe

[Therapeutic Advances in Infectious Disease @TAInfDis]

Scrofuloderma can mimic hidradenitis suppurativa and other chronic skin diseases. This case highlights the need to consider TB in atypical recurrent skin lesions
https://t.co/wLLhw2ysZi

[Therapeutic Advances in Infectious Disease @TAInfDis]

Among graduating healthcare students at Debre Tabor University:
💊 68% bought antibiotics without a prescription
🧠 Only 32.5% recognized antimicrobial stewardship (AMS)
Knowledge alone isn’t enough
https://t.co/qRcDB96n7T

[Therapeutic Advances in Infectious Disease @TAInfDis]

In a cohort from Gulu City, 45.4% experienced viral non-suppression, driven by poor ART adherence, delayed HIV disclosure, advanced disease, young age, and economic hardship.
https://t.co/NPC6OWLYVS

[Therapeutic Advances in Infectious Disease @TAInfDis]

New systematic review & meta-analysis in SSA HCWs shows moderate AMR knowledge (65%) and attitudes (69%), but weaker practices (54%), with a clear knowledge–practice gap—most evident among doctors (knowledge 65%, practice 43%).
https://t.co/xbDfdahzoC

[Therapeutic Advances in Infectious Disease @TAInfDis]

Meet our Biostatistical Editor, Theophilus I. Emeto @ti_Emeto 📊
Featured today ! 👇
#InfectiousDiseases #Biostatistics #EditorialSpotlight

[Therapeutic Advances in Infectious Disease @TAInfDis]

✨ Introducing our Editorial Spotlight Series
👀 Meet the people behind the science
What motivates them 🚀 What inspires them 🌱
What brings them joy 🎶Because great work starts with real people ❤️Stay tuned as we highlight our team!
#EditorialSpotlight

[Therapeutic Advances in Infectious Disease @TAInfDis]

TB treatment is evolving—but persistence remains a major barrier. New evidence shows macrophage metabolism and redox state shape intracellular drug tolerance in Mtb. Host-directed strategies may enhance antibiotic efficacy and help shorten therapy ⏳
https://t.co/63qZoegbum

[Therapeutic Advances in Infectious Disease @TAInfDis]

Case report: a young patient with years of “chronic lung disease” ultimately diagnosed with aggressive HTLV-1 driven lymphoma-fatal within weeks. Early biopsy + T-cell panel (CD4+CD25+ with CD7 loss) should trigger HTLV-1 testing, regardless of geography.
https://t.co/MB0JOo5CS7

[Therapeutic Advances in Infectious Disease @TAInfDis]

CKD and UTIs form a vicious cycle: kidney dysfunction increases infection risk ; while recurrent UTIs accelerate renal decline. Breaking this loop demands early CKD detection, antimicrobial stewardship & non-antibiotic prevention strategies.
https://t.co/tGV6m0n68x

[Therapeutic Advances in Infectious Disease @TAInfDis]

Neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) are valuable, readily available markers for gauging severity in community-acquired pneumonia 🦠📊
https://t.co/WyLykt16xo

[Therapeutic Advances in Infectious Disease @TAInfDis]

Prospective study (Ukraine/Moldova/Spain, n=287): mfloDx™ MDR-TB assay achieved Se 100% / Sp 98.7% for INH+RIF resistance vs culture DST. Caveat: 35% inconclusive results. Potential role as rapid screening tool.
https://t.co/FpaKBpfg2q

[Therapeutic Advances in Infectious Disease @TAInfDis]

Does EV-D68 amplify TB immunopathology?
Case series suggests coinfection may worsen lung inflammation, with clinical response seen after corticosteroid escalation.
A reminder to consider viral triggers in atypical TB courses.
https://t.co/8DFY8ErhsM

[Therapeutic Advances in Infectious Disease @TAInfDis]

Arboviruses don’t act in isolation 🦟 Chikungunya and Zika spread where structural vulnerabilities persist—limited surveillance, inequity, and inadequate sanitation. Future resilience depends on integrating social and biological surveillance systems 🧬.https://t.co/HCKa27QHw5

[Therapeutic Advances in Infectious Disease @TAInfDis]

Diagnosing invasive mold infections 🧫 in immunocompromised patients remains difficult.NGS 🧬 offers noninvasive, actionable insights-identifying missed infections and guiding therapy in over half of cases.
https://t.co/snFqifXqQ7

[Therapeutic Advances in Infectious Disease @TAInfDis]

Malaria 🦟 + soil-transmitted helminths 🪱 often co-infect young children in Nigeria, driving early red cell changes 🩸 before overt anaemia. Host factors esp haemoglobin genotype 🧬matter more than parasite load. https://t.co/7JFdcMtDkF

[Therapeutic Advances in Infectious Disease @TAInfDis]

New meta-analysis 📊: HBV escape mutations are common in LMICs
🧬 Immune escape ~56%
💊 Resistance highest with 3TC/LdT
https://t.co/anIXoQy6Z3